U.S., March 8 -- ClinicalTrials.gov registry received information related to the study (NCT06863701) titled 'Efficacy Anda Safety of Etoricoxib With Betamethasone for the Treatment of Acute Gout Arthritis' on March 03.
Brief Summary: Phase III longitudinal, multicenter, randomized, double-blind clinical trial. The aim of this study is to evaluate the efficacy and safety of the Fixed-Dose Combination of Etoricoxib/Betamethasone Versus Etoricoxib in Patients With Acute Gouty Arthritis
Study Start Date: Jan. 27
Study Type: INTERVENTIONAL
Condition:
Gout Arthritis
Gout Attack
Intervention:
DRUG: Etoricoxib + Betamethasone fixed dose
One tablet of 90 mg / 0.25 mg a day
DRUG: Etoricoxib fixed dose
One pill of 90 mg a day
Recruitment St...